A Study Assessing KB304 for the Treatment of Wrinkles in Women
← catalyst calendarSponsored by Krystal Biotech, Inc. (industry) · KRYS — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
19actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-20 | actual | When the study began enrolling |
| Primary completion | Jul 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Wrinkles in Decolletage
- Pigmentation
- Décolleté Wrinkles
Interventions
- Biological: KB304
- Drug: 0.9% Normal Saline (NS)
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability of KB304 versus placebo administered by intradermal injection
measured Up to 4 months
Permalink · KRYS's whole pipeline · Catalyst calendar · Every registered study · What changed